Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Gesa Schalk"'
Autor:
Sarina Butzer, Imke Hennies, Charlotte Gimpel, Jutta Gellermann, Gesa Schalk, Sabine König, Anja K. Büscher, Anja Lemke, Martin Pohl
Publikováno v:
BMC Pediatrics, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background IgA vasculitis (IgAV) is the most common form of systemic vasculitis in childhood and frequently involves the kidney. A minority of patients with IgA vasculitis nephritis (IgAVN), especially those presenting with heavy proteinuria
Externí odkaz:
https://doaj.org/article/6fb6d99858354840862069921b6d5e85
Publikováno v:
Immunity & Ageing, Vol 16, Iss 1, Pp 1-8 (2019)
Abstract Background Older age at organ transplantation is associated with increased risk of infection and malignancy but reduced risk of cellular rejection. De novo donor-specific anti-HLA antibodies (dnDSA), are key biomarkers associated with reduce
Externí odkaz:
https://doaj.org/article/91c6f17fe407489fa1bd0d81512f2eff
Autor:
Fei Zhao, Sara Afonso, Susanne Lindner, Andrea Hartmann, Ina Löschmann, Bo Nilsson, Kristina N. Ekdahl, Lutz T. Weber, Sandra Habbig, Gesa Schalk, Michael Kirschfink, Peter F. Zipfel, Christine Skerka
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
C3 glomerulopathy (C3G) is a severe kidney disease, which is caused by defective regulation of the alternative complement pathway. Disease pathogenesis is heterogeneous and is caused by both autoimmune and genetic factors. Here we characterized IgG a
Externí odkaz:
https://doaj.org/article/5d550f1fe1af4ecaa888ba08162e924f
Autor:
Gema Ariceta, Laure Collard, Saoussen Abroug, Shabbir H. Moochhala, Edward Gould, Abir Boussetta, Mohamed Ben Hmida, Sudarsana De, Tracy E. Hunley, Faical Jarraya, Gloria Fraga, Ana Banos, Elisabeth Lindner, Bastian Dehmel, Gesa Schalk
Publikováno v:
PEDIATRIC NEPHROLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Scientia
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Scientia
Background Primary hyperoxalurias (PHs) are rare genetic diseases that increase the endogenous level of oxalate, a waste metabolite excreted predominantly by the kidneys and also the gut. Treatments aim to improve oxalate excretion, or reduce oxalate
Autor:
David S. Goldfarb, John C. Lieske, Jaap Groothoff, Gesa Schalk, Kerry Russell, Shuli Yu, Blaz Vrhnjak
Publikováno v:
Urolithiasis. 51
Nedosiran is an N-acetyl-D-galactosamine (GalNAc)–conjugated RNA interference agent targeting hepatic lactate dehydrogenase (encoded by the LDHA gene), the putative enzyme mediating the final step of oxalate production in all three genetic subtypes
Autor:
David J. Sas, Daniella Magen, Wesley Hayes, Hadas Shasha-Lavsky, Mini Michael, Indra Schulte, Anne-Laure Sellier-Leclerc, Jiandong Lu, Ali Seddighzadeh, Bahru Habtemariam, Tracy L. McGregor, Kenji P. Fujita, Yaacov Frishberg, Justine Bacchetta, Véronique Baudouin, Rachel Becker-Cohen, Shimrit Tzvi Behr, Efrat Ben-Shalom, Maria Berdaguer, Detlef Bockenhauer, Pierre Cochat, Martin Coenen, Carl H. Cramer, Georges Deschênes, Claire Dossier, Emilie Doye, Liat Feraru Feldman, Maximilian Hohenadel, Florentia Kaguelidou, Irina Libinson Zebegret, John C. Lieske, Anne Maisin, Dawn S. Milliner, Moran Plonsky Toder, Shirley Pollack, Aurélie Portefaix, Bruno Ranchin, Choni Rinat, Adnan Safdar, Gesa Schalk, Poyyapakkam R. Srivaths, Cheryl L. Tran, William Van't Hoff, Jenny Weinbrand-Goichberg, Irith Weissman
Publikováno v:
Genetics in Medicine. 24:654-662
Primary hyperoxaluria type 1 (PH1) is a rare, progressive, genetic disease with limited treatment options. We report the efficacy and safety of lumasiran, an RNA interference therapeutic, in infants and young children with PH1.This single-arm, open-l
Autor:
Pushkal Garg, William O'Riordan, Sally A. Hulton, John C. Lieske, Jaap W. Groothoff, Eva Simkova, Hadas Shasha-Lavsky, Sander F. Garrelfs, Akshay Vaishnaw, Gesa Schalk, John M. Gansner, Kristin Meliambro, Pierre Cochat, Daniella Magen, Daniel Guido Fuster, Marianne T. Sweetser, William van’t Hoff, Jiandong Lu, Michael J. Koren, Yaacov Frishberg, Jeffrey M. Saland, Shabbir H. Moochhala, Georges Deschênes, Tracy L. McGregor, David J. Sas
Publikováno v:
New England journal of medicine, 384(13), 1216-1226. Massachussetts Medical Society
Background: Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by hepatic overproduction of oxalate that leads to kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. Lumasiran, an investigational RNA interference
Autor:
Martin Coenen, Craig B. Langman, Bernd Hoppe, Michelle A. Baum, Kelly Barrios, David McDougall, Annelize Koch, Sander F. Garrelfs, Aniruddha Amrite, Jaap W. Groothoff, Graham Lipkin, Gesa Schalk, Pierre Cochat
Publikováno v:
Kidney international. Nature Publishing Group
Primary hyperoxaluria (PH) is a family of ultra-rare autosomal recessive inherited disorders of hepatic glyoxylate metabolism characterized by oxalate overproduction. Nedosiran is an RNA interference agent that inhibits hepatic lactate dehydrogenase,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45f77e773f290169ac0ad9c5fbd8d9ca
https://pure.amc.nl/en/publications/safety-pharmacodynamics-and-exposureresponse-modeling-results-from-a-firstinhuman-phase-1-study-of-nedosiran-phyox1-in-primary-hyperoxaluria(1c7005ba-03d0-46d6-9341-a3ec4ee99611).html
https://pure.amc.nl/en/publications/safety-pharmacodynamics-and-exposureresponse-modeling-results-from-a-firstinhuman-phase-1-study-of-nedosiran-phyox1-in-primary-hyperoxaluria(1c7005ba-03d0-46d6-9341-a3ec4ee99611).html
Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders
Autor:
Cyrill Wehling, Oliver Amon, Rolf Weimer, Martin Bommer, Rainer Büscher, Burkhard Tönshoff, Karim Kentouche, Michael Kirschfink, Michael S. Wiesener, Ömer-Necmi Gök, Bernd Hoppe, Gesa Schalk, Henry Fehrenbach, Bernd Hohenstein
Publikováno v:
Clinical and Experimental Immunology. 187:304-315
Summary Various complement-mediated renal disorders are treated currently with the complement inhibitor eculizumab. By blocking the cleavage of C5, this monoclonal antibody prevents cell damage caused by complement-mediated inflammation. We included
Autor:
Henry Fehrenbach, Jens Koenig, Sabine Schmidt, Max C. Liebau, Lisa Loechtermann, Brigitta Kranz, Martin Konrad, Rasmus Ehren, Lars Pape, Kay Latta, M Pohl, Tim Friede, Evelin Muschiol, Frauke Wilkening, Christian Lerch, Mirja Wedekin, Reinhard Hilgers, Jenny Frese, Markus Feldkoetter, Matthias Kettwig, Julia Thumfart, Sabine Ponsel, Peter F. Hoyer, Ulrike John, Jutta Gellermann, Joseph Sonntag, Michaela Gessner, Susanne Klaiber, Katja Sauerstein, Baerbel Lange-Sperandio, Oliver Gross, Britta Hoecker, Therese Jungraithmayr, Anne Kristin Vogt-Weigeldt, Jan Boeckhaus, Carsten Paul Bramlage, Clifford E. Kashtan, Sabine U. König, Ralf Husain, Frauke Weber, Heiko Billing, Ulrike Jacoby, Bernd Hoppe, Gesa Schalk, Burkhard Tönshoff, Michael Koziolek, Hildegard Zappel, Katrin Mueller, Matthias Galiano, Lutz T. Weber, Matthias Hansen, Markus Harden, Tanja Albrecht-Nock, Hagen Staude, Nicole C. Meyer
Publikováno v:
Kidney international. 97(6)
Corrected Proof Children with Alport syndrome develop renal failure early in life. Since the safety and efficacy of preemptive nephroprotective therapy are uncertain we conducted a randomized, placebo-controlled, double-blind trial in 14 German sites